Adrenergic modulation of potassium metabolism in uremia

Pietro Castellino, Margaret J. Bia, Ralph A Defronzo

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The effect of chronic beta adrenergic blockade on potassium homeostasis during moderate intensity exercise (40% of VO2 max) was examined in seven end-stage renal patients who were being maintained on chronic dialysis treatment. Subjects participated in three study protocols: 1) exercise alone, 2) exercise plus propranolol (a nonselective beta-1, beta-2 antagonist), and 3) exercise plus metoprolol (a specific beta-1 antagonist). The basal potassium concentration was similar in all three studies and averaged 4.95 ± 0.12 mEq/liter. During Study 1 (exercise alone), plasma potassium rose by 0.26 ± 0.09 mEq/liter. During exercise with propranolol, plasma K concentration rose significantly higher (Δ plasma K = 0.44 ± 0.26 mEq/liter; P < 0.05 vs. exercise alone). In contrast, the rise in plasma K during exercise with metoprolol (Δ plasma K = 0.20 ± 0.08 mEq/liter) was similar to that observed with exercise alone. Differences in potassium homeostasis between metoprolol and propranolol could not be explained by differences in hemodynamic parameters, levels of potassium regulatory hormones, or acid base status. Thus, the higher rise in potassium concentration during exercise with propranolol could only be explained by adrenergic blockade at the beta-2 receptor site. These results support the concept that adrenergic control of extrarenal potassium homeostasis in dialysis patients is mediated at the beta-2 receptor. Since a deterioration in potassium homeostasis during exercise is observed with beta-2, but not beta-1 blockade, selective beta-1 adrenergic blocking agents may be safer in dialysis patients.

Original languageEnglish (US)
Pages (from-to)793-798
Number of pages6
JournalKidney International
Volume37
Issue number2
StatePublished - Feb 1990

Fingerprint

Uremia
Adrenergic Agents
Potassium
Exercise
Propranolol
Metoprolol
Homeostasis
Dialysis
Adrenergic beta-1 Receptor Antagonists
Hemodynamics
Hormones
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Adrenergic modulation of potassium metabolism in uremia. / Castellino, Pietro; Bia, Margaret J.; Defronzo, Ralph A.

In: Kidney International, Vol. 37, No. 2, 02.1990, p. 793-798.

Research output: Contribution to journalArticle

Castellino, P, Bia, MJ & Defronzo, RA 1990, 'Adrenergic modulation of potassium metabolism in uremia', Kidney International, vol. 37, no. 2, pp. 793-798.
Castellino, Pietro ; Bia, Margaret J. ; Defronzo, Ralph A. / Adrenergic modulation of potassium metabolism in uremia. In: Kidney International. 1990 ; Vol. 37, No. 2. pp. 793-798.
@article{3f0f3c00ba0944f0bf57543a316525ce,
title = "Adrenergic modulation of potassium metabolism in uremia",
abstract = "The effect of chronic beta adrenergic blockade on potassium homeostasis during moderate intensity exercise (40{\%} of VO2 max) was examined in seven end-stage renal patients who were being maintained on chronic dialysis treatment. Subjects participated in three study protocols: 1) exercise alone, 2) exercise plus propranolol (a nonselective beta-1, beta-2 antagonist), and 3) exercise plus metoprolol (a specific beta-1 antagonist). The basal potassium concentration was similar in all three studies and averaged 4.95 ± 0.12 mEq/liter. During Study 1 (exercise alone), plasma potassium rose by 0.26 ± 0.09 mEq/liter. During exercise with propranolol, plasma K concentration rose significantly higher (Δ plasma K = 0.44 ± 0.26 mEq/liter; P < 0.05 vs. exercise alone). In contrast, the rise in plasma K during exercise with metoprolol (Δ plasma K = 0.20 ± 0.08 mEq/liter) was similar to that observed with exercise alone. Differences in potassium homeostasis between metoprolol and propranolol could not be explained by differences in hemodynamic parameters, levels of potassium regulatory hormones, or acid base status. Thus, the higher rise in potassium concentration during exercise with propranolol could only be explained by adrenergic blockade at the beta-2 receptor site. These results support the concept that adrenergic control of extrarenal potassium homeostasis in dialysis patients is mediated at the beta-2 receptor. Since a deterioration in potassium homeostasis during exercise is observed with beta-2, but not beta-1 blockade, selective beta-1 adrenergic blocking agents may be safer in dialysis patients.",
author = "Pietro Castellino and Bia, {Margaret J.} and Defronzo, {Ralph A}",
year = "1990",
month = "2",
language = "English (US)",
volume = "37",
pages = "793--798",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Adrenergic modulation of potassium metabolism in uremia

AU - Castellino, Pietro

AU - Bia, Margaret J.

AU - Defronzo, Ralph A

PY - 1990/2

Y1 - 1990/2

N2 - The effect of chronic beta adrenergic blockade on potassium homeostasis during moderate intensity exercise (40% of VO2 max) was examined in seven end-stage renal patients who were being maintained on chronic dialysis treatment. Subjects participated in three study protocols: 1) exercise alone, 2) exercise plus propranolol (a nonselective beta-1, beta-2 antagonist), and 3) exercise plus metoprolol (a specific beta-1 antagonist). The basal potassium concentration was similar in all three studies and averaged 4.95 ± 0.12 mEq/liter. During Study 1 (exercise alone), plasma potassium rose by 0.26 ± 0.09 mEq/liter. During exercise with propranolol, plasma K concentration rose significantly higher (Δ plasma K = 0.44 ± 0.26 mEq/liter; P < 0.05 vs. exercise alone). In contrast, the rise in plasma K during exercise with metoprolol (Δ plasma K = 0.20 ± 0.08 mEq/liter) was similar to that observed with exercise alone. Differences in potassium homeostasis between metoprolol and propranolol could not be explained by differences in hemodynamic parameters, levels of potassium regulatory hormones, or acid base status. Thus, the higher rise in potassium concentration during exercise with propranolol could only be explained by adrenergic blockade at the beta-2 receptor site. These results support the concept that adrenergic control of extrarenal potassium homeostasis in dialysis patients is mediated at the beta-2 receptor. Since a deterioration in potassium homeostasis during exercise is observed with beta-2, but not beta-1 blockade, selective beta-1 adrenergic blocking agents may be safer in dialysis patients.

AB - The effect of chronic beta adrenergic blockade on potassium homeostasis during moderate intensity exercise (40% of VO2 max) was examined in seven end-stage renal patients who were being maintained on chronic dialysis treatment. Subjects participated in three study protocols: 1) exercise alone, 2) exercise plus propranolol (a nonselective beta-1, beta-2 antagonist), and 3) exercise plus metoprolol (a specific beta-1 antagonist). The basal potassium concentration was similar in all three studies and averaged 4.95 ± 0.12 mEq/liter. During Study 1 (exercise alone), plasma potassium rose by 0.26 ± 0.09 mEq/liter. During exercise with propranolol, plasma K concentration rose significantly higher (Δ plasma K = 0.44 ± 0.26 mEq/liter; P < 0.05 vs. exercise alone). In contrast, the rise in plasma K during exercise with metoprolol (Δ plasma K = 0.20 ± 0.08 mEq/liter) was similar to that observed with exercise alone. Differences in potassium homeostasis between metoprolol and propranolol could not be explained by differences in hemodynamic parameters, levels of potassium regulatory hormones, or acid base status. Thus, the higher rise in potassium concentration during exercise with propranolol could only be explained by adrenergic blockade at the beta-2 receptor site. These results support the concept that adrenergic control of extrarenal potassium homeostasis in dialysis patients is mediated at the beta-2 receptor. Since a deterioration in potassium homeostasis during exercise is observed with beta-2, but not beta-1 blockade, selective beta-1 adrenergic blocking agents may be safer in dialysis patients.

UR - http://www.scopus.com/inward/record.url?scp=0025099357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025099357&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 793

EP - 798

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -